Morgan Stanley’s VITAE PHARMACEUTICALS INC COMMON STOCK VTAE Stock Holding History

Morgan Stanley’s Portfolio VTAE Stock Details VTAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-199,065	Closed	-$4.16M	–	6691
2016 Q3	$4.16M	Buy	199,065 +190,883	+2,333%	+$2.2M	﹤0.01%	2843
2016 Q2	$88K	Sell	8,182 -63,469	-89%	-$543K	﹤0.01%	5297
2016 Q1	$475K	Buy	71,651 +56,262	+366%	+$512K	﹤0.01%	4483
2015 Q4	$279K	Buy	15,389 +6,507	+73%	+$89.5K	﹤0.01%	4904
2015 Q3	$98K	Buy	8,882 +5,377	+153%	+$57.1K	﹤0.01%	5431
2015 Q2	$50K	Sell	3,505 -2,721	-44%	-$37K	﹤0.01%	5850
2015 Q1	$73K	Sell	6,226 -18,182	-74%	-$245K	﹤0.01%	5658
2014 Q4	$406K	Buy	+24,408	New	+$357K	﹤0.01%	4825

Morgan Stanley's VTAE Position: Q4 2016 in Review

Morgan Stanley sold out of VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) in Q4 2016, closing a stake of 199,065 shares — an estimated $4.16M sold.

Morgan Stanley first reported a position in VTAE in Q4 2014 and held it in 8 quarters. The position peaked at $4.16M in Q3 2016. 0 funds tracked by Wall St. Rank hold VTAE as of Q4 2016.

Morgan Stanley reported no remaining VITAE PHARMACEUTICALS INC COMMON STOCK position as of Q4 2016 after selling out during the quarter.
Morgan Stanley sold 199,065 VITAE PHARMACEUTICALS INC COMMON STOCK shares in Q4 2016, an estimated $4.16M.
Morgan Stanley first reported a position in VITAE PHARMACEUTICALS INC COMMON STOCK in Q4 2014 and held it in 8 quarters.
Morgan Stanley's VITAE PHARMACEUTICALS INC COMMON STOCK position peaked at $4.16M in Q3 2016.
0 funds tracked by Wall St. Rank held VITAE PHARMACEUTICALS INC COMMON STOCK as of Q4 2016.

Based on Morgan Stanley's 13F filing for Q4 2016, filed 13 Feb 2017.